AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

CEO Dr. Srinivas Rao to discuss late-stage clinical development, regulatory considerations, and commercial adoption of psychedelic-based therapies

Apr. 14, 2026 at 10:23am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the intricate structures and pathways of the human brain, conceptually representing the innovative psychedelic-based therapies being developed by AtaiBeckley.An X-ray view into the complex neural networks of the brain, hinting at the potential of psychedelic-based therapies to unlock new frontiers in mental health treatment.NYC Today

AtaiBeckley, a clinical-stage biotechnology company focused on developing rapid-acting mental health treatments, announced that its Co-Founder and CEO Dr. Srinivas Rao will participate in upcoming Needham Healthcare Conferences. Dr. Rao will discuss the company's pipeline, including its lead candidate BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, which is on track to enter Phase 3 studies in Q2 2026.

Why it matters

AtaiBeckley's participation in these high-profile healthcare conferences highlights the growing interest and momentum around psychedelic-based therapies as a potential solution for mental health conditions. The discussions will provide insights into the clinical development, regulatory landscape, and commercialization challenges facing this emerging field.

The details

Dr. Rao will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 16th, as well as a panel discussion at the Needham Virtual Psychedelics Forum on April 27th. The panel will focus on topics such as late-stage clinical development strategy, FDA and DEA regulatory considerations, payer economics, and the long-term commercial adoption of psychedelic-based therapies like AtaiBeckley's BPL-003.

  • The 25th Annual Needham Virtual Healthcare Conference will take place from April 13-16, 2026.
  • The Needham Virtual Psychedelics Forum will be held on April 27, 2026.

The players

AtaiBeckley Inc.

A clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments.

Dr. Srinivas Rao

Co-Founder and Chief Executive Officer of AtaiBeckley.

Got photos? Submit your photos here. ›

What they’re saying

“Topics for the panel will focus on late-stage clinical development strategy, FDA and DEA regulatory considerations, payer economics, and the long-term commercial adoption of psychedelic-based therapies such as BPL-003, AtaiBeckley's intranasal formulation of mebufotenin benzoate which holds FDA Breakthrough Therapy Designation and is on track to enter Phase 3 studies in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA.”

— Dr. Srinivas Rao, Co-Founder and Chief Executive Officer

What’s next

AtaiBeckley's lead candidate BPL-003 is on track to enter Phase 3 clinical trials in the second quarter of 2026, following a successful End-of-Phase 2 meeting with the FDA.

The takeaway

AtaiBeckley's participation in these high-profile healthcare conferences underscores the growing interest and potential of psychedelic-based therapies as a novel approach to addressing mental health conditions. The discussions will provide valuable insights into the clinical development, regulatory landscape, and commercialization challenges facing this emerging field.